Drugs listed with a risk-sharing agreement in Korea (Dec 2013-August 2017) Amounts saved by risk-sharing agreement (2014-2016) Abbreviation: RSA (risk-sharing agreement); PE (pharmacoeconomics); CED (Coverage with evidence development) An expert stated that the extension of risk-sharing agreements (RSA) and the establishment of a post-assessment system for new drugs can overcome the limitation of economic feasibility tests. Ahn said the RSA system allowed local patients to access new drugs without the risk of a multinational pharmaceutical company excluding Korea from the drug supply. It also guarantees the risk of a pharmaceutical company setting a low drug price in a third country that refers to drug prices in Korea, he said. RSA refers to an agreement between a pharmaceutical company and the National Health Insurance Service (NHIS) to take responsibility for uncertainties regarding the efficacy of the drug. Abstract: TA (total, 100 mil. KRW); KRW (Korean won); GR (growth rate, %); DE (Drug-related expenses); ME (medical expenses); NT (total expenses); RSA (Risk Sharing Agreement) Due to the approach to re-evaluating approved drugs under the Risk Sharing Agreements (RSA), experts are actively discussing how to improve the RSA system. The risk-sharing system is called RSAs (Risk Shared Agreements), PBAs (performancebased Agreements) and PAS (Patent Access Systems) depending on the objective and purpose of each country.5) The risk action system is used to determine the insurance benefits of new drugs (UK, Italy, Australia and Canada) reviewed the risk-taking system and found that the objective of implementing the system was to manage financial risk while improving access to patients to new drugs.6-9) Risk-taking systems are implemented in different ways. , based on the new drug list process and the health environment in each country. , can be subdivided into health-based types of contracts and types.
However, in most countries, with the exception of Italy, venture equity contracts based on financial loans are actively entered into for practical reasons such as system application and post-management.7,10,11) The reason financially based risk equity contracts are activated is that pharmaceutical companies prefer to increase the price of the display because large countries determine prices using foreign prices and the results of foreign prices evaluation have been identified as the main causes that favour financial risk contracts. Finally, the financial base risk-taking contract can keep the display price in the pharmaceutical position, the patient`s point of view is better access to medicines, the government position is widely used as a system capable of meeting all stakeholder interests, as it can spread financial risks. This study examined the Risk Sharing Agreement (RSA) on the pharmaceutical system in Korean legal health insurance. RSA has enabled the insurer to maintain the principles of the price list process, while effectively managing the budget and improving patient access to new drugs. Despite these positive effects, some stakeholders continue to raise issues, such as the lack of transparency in the list process and doubts about its effectiveness. That`s why we studied the impact of RSA on national health insurance funding and patient access to analyze the effects of RSA. This study was conducted with support from the Korea Global Pharmaceutical Industry Association. The opinions of this study are those of the authors and may differ from those of the research funding agency. New drug list method in Korea health insurance only benefits from inexpensive drugs with a selection system (positive system).